Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

• Main Authors: José Diogo S. Souza (Author), Antonio W. Zuardi (Author), Francisco S. Guimarães (Author), Flávia de Lima Osório (Author), Sonia Regina Loureiro (Author), Alline Cristina Campos (Author), Jaime E. C. Hallak (Author), Rafael G. Dos Santos (Author), Isabella Lara Machado Silveira (Author), Karina Pereira-Lima (Author), Julia Cozar Pacheco (Author), Juliana Mayumi Ushirohira (Author), Rafael Rinaldi Ferreira (Author), Karla Cristinne Mancini Costa (Author), Davi Silveira Scomparin (Author), Franciele Franco Scarante (Author), Isabela Pires- (Author), Raphael Mechoulam (Author), Flávio Kapczinski (Author), Benedito A. L. Fonseca (Author), Danillo L. A. Esposito (Author), Maristela Haddad Andraus (Author), José Alexandre S. Crippa (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation.Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two st...